EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

The Impact of Nanobodies on G Protein–Coupled Receptor Structural Biology and Their Potential as Therapeutic Agents

David Salom, Arum Wu, Chang C Liu, Krzysztof Palczewski

Molecular Pharmacology · 2024-10 · 106 (4) · 155-163

DOI: 10.1124/molpharm.124.000974 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Pharmacology, 2024-10. Verfasst von David Salom und 3 weiteren Autor:innen. Beteiligte Einrichtung: Gavin Herbert Eye Institute - Center for Translational Vision Research, Department of Ophthalmology (D.S., A.W., K.P.) and Department of Biomedical E…. Hauptthemen laut MEDLINE: Single-Domain Antibodies, Receptors, G-Protein-Coupled. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NEI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The family of human G protein-coupled receptors (GPCRs) comprises about 800 different members, with about 35% of current pharmaceutical drugs targeting GPCRs. However, GPCR structural biology, necessary for structure-guided drug design, has lagged behind that of other membrane proteins, and it was not until the year 2000 when the first crystal structure of a GPCR (rhodopsin) was solved. Starting in 2007, the determination of additional GPCR structures was facilitated by protein engineering, new crystallization techniques, complexation with antibody fragments, and other strategies. More recently, the use of camelid heavy-chain-only antibody fragments (nanobodies) as crystallographic chaperones has revolutionized the field of GPCR structural biology, aiding in the determination of more than 340 GPCR structures to date. In most cases, the GPCR structures solved as complexes with nanobodies (Nbs) have revealed the binding mode of cognate or non-natural ligands; in a few cases, the same Nb has acted as an orthosteric or allosteric modulator of GPCR signaling. In this review, we summarize the multiple ingenious strategies that have been conceived and implemented in the last decade to capitalize on the discovery of nanobodies to study GPCRs from a structural perspective. SIGNIFICANCE STATEMENT: G protein-coupled receptors (GPCRs) are major pharmacological targets, and the determination of their structures at high resolution has been essential for structure-guided drug design and for insights about their functions. Single-domain antibodies (nanobodies) have greatly facilitated the structural determination of GPCRs by forming complexes directly with the receptors or indirectly through protein partners.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Single-Domain AntibodiesReceptors, G-Protein-CoupledHumansAnimalsLigandsProtein Conformation

Substanzen

Single-Domain AntibodiesReceptors, G-Protein-CoupledLigands

Autor:innen und Institutionen

  • Gavin Herbert Eye Institute - Center for Translational Vision Research, Department of Ophthalmology (D.S., A.W., K.P.) and Department of Biomedical Engineering (C.C.L.), University of California, Irvine, Irvine, Califor…

Förderung

  • NEI NIH HHS

Zitieren

APA

Salom, D., Wu, A., Liu, C. C., & Palczewski, K. (2024). The Impact of Nanobodies on G Protein–Coupled Receptor Structural Biology and Their Potential as Therapeutic Agents. Molecular Pharmacology, 106(4), 155-163. https://doi.org/10.1124/molpharm.124.000974

Vancouver

Salom D, Wu A, Liu CC, Palczewski K. The Impact of Nanobodies on G Protein–Coupled Receptor Structural Biology and Their Potential as Therapeutic Agents. Molecular Pharmacology. 2024;106(4):155-163. doi:10.1124/molpharm.124.000974

BibTeX
@article{Salom2024,
  author = {Salom, David and Wu, Arum and Liu, Chang C and Palczewski, Krzysztof},
  title = {The Impact of Nanobodies on G Protein–Coupled Receptor Structural Biology and Their Potential as Therapeutic Agents},
  journal = {Molecular Pharmacology},
  year = {2024},
  volume = {106},
  number = {4},
  pages = {155--163},
  doi = {10.1124/molpharm.124.000974}
}
Kostenlos starten →